Avoiding Anticoagulation After IntraCerebral Haemorrhage
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant
drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
(AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH).
Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular
non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an
intracerebral haemorrhage.
Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should
start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid
anticoagulation and LAAC.